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Background
Recombinant therapeutic proteins are usually produced
by cell culture technology using genetically modified
host cell lines. During the manufacturing process, a mix-
ture of the protein of interest and host cell derived
impurities, including host cell proteins (HCPs) and
other process related impurities are produced. Those
process related impurities will be cleared or minimized
though the process by optimization of process purifica-
tion. Residual HCPs in the final drug substance may
affect the quality, safety and efficacy and may result in
clinical adverse effects. HCPs are typically quantified
using immunoassays such as enzyme-linked immunosor-
bent assay (ELISA). The development and the validation
of those assays are really challenging mainly due to the
wide variety of possible HCPs in products. Although
generic ELISA kits are commercially available to quan-
tify HCPs from different recombinant systems, a process
specific assay is required before drug registration and
commercialization for biologics. The reagents, polyclonal
antibodies and HCP standards, need to be carefully pre-
pared and characterized to ensure a correct quantitation
of the HCPs in the final product. Here we describe the
first step of the development of a production platform-
specific HCP-ELISA assay for UCB’s biopharmaceuticals
produced in a Chinese Hamster Ovary (CHO) cell line,
i.e. the production of mock material containing the
HCPs using a null cell line.
Materials and methods
2L and 80L stirred tank bioreactors (Sartorius) were run
for 14 days in a fed-batch mode in a chemically defined
medium. Feed was added daily from day 3 onwards. If
required, antifoam was added to the bioreactor by manual
injections. Dissolved Oxygen (DO), pH, and temperature
were controlled at set points. DO was controlled using a
multi-stage aeration cascade via a ring sparger. Viable cell
concentration and cell viability were measured using a
ViCell cell counter (Beckman Coulter). The osmolality
was measured using an osmometer (Advanced Instru-
ments).The off-line pH was measured using a BioProfile-
pHOx (Nova Biomedical). The glucose, lactate, glutamine
and ammonia concentrations were measured with a Bio-
Profile Analyzer 400 (Nova Biomedical). On the day of
harvest, the clarification was performed by centrifugation,
depth filtration and sterile filtration. Part of the material
was further clarified by tangential flow filtration (TFF) on
the Uniflux 10 system (GE Life Sciences) using low mole-
cular weight cut-off membranes and concentrated before
being diafiltered into an appropriate buffer.
The antigens from the mock run were assessed for
their total HCP content by 2D DIGE and analyzed by
the DeCyderTM 2D 7.2 software.
Results
Different feeding strategies have been assessed at 2L scale
to select the best condition enabling obtaining comparable
cell growth and metabolite profiles between the null cells
and three cell lines derived from our recombinant plat-
form and expressing different mAbs (Cell lines mAb1,
mAb2 and mAb3). The three feeding strategies assessed
were the center point process (CPP), CPP+20% and CPP-
20%. Viable cell density, cell viability, off-line pH, glucose,
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lactate glutamine, ammonia and osmolality levels have
been monitored throughout the cultures and the HCP
profiles of the cell pellet and supernatant material were
assessed by 2-D Fluorescence Differential Gel Electrophor-
esis (2D-DIGE) analysis. The gels of each of the samples
were analyzed to assess the spot coverage percentage and
to obtain a qualitative HCP profile of each of supernatant
and cell pellet. These profiles were reproducible between
gels which meant both in-gel and inter-gel analysis could
be performed. Based on the spot coverage (Table 1) and
the intensity, the HCP profiles were comparable with
slight differences between the feeding strategies. Based on
the process performance output parameters and HCP pro-
files, the Center Point Process (CPP) feeding strategy was
selected to be applied on the mock production in 80L stir-
red tank bioreactors. The null cell line output parameter
profiles were comparable between the two scales, 2L and
80L bioreactors. Moreover, the cell growth profiles of the
mock run were comparable to the antibody producing cell
lines. After mock materiel production at 80L scale, the
mock harvest, the concentrated harvest and the cell pellet
were compared using 2D-DIGE to evaluate the common
spots between the different antigens. The comparison has
been made against the concentrated harvest material as
this is most representative of the total HCP profile (Figure
1). Around 57% of the spots found in the cell pellet extract
were similar to those found in the concentrated harvest
whereas around 72% of the mock harvest spots were simi-
lar to concentrated harvest spots.
Conclusions
A crucial step of the development of a platform HCP-
ELISA assay is to set-up the mock cell run conditions to
obtain comparable cell growth, hence comparable HCP
profiles the null cell and production cell lines. Here, we
optimized the mock upstream conditions at 2L scale
and scaled up at 80L scale. We demonstrated that the
mock cell line growth and HCP profiles are comparable
at both scales, 2L and 80L respectively. In addition, we
have shown that the HCP profiles were also comparable
Table 1 Comparison of spot coverage within the same gel of the supernatant and the cell pellet samples, for both
feeding strategies CPP and CPP-20%
Null cell line CPP (2L scale) Null cell line CPP-20% (2L scale)
% of spot coverage in the supernatant 71 72
% of spot coverage in the supernatant 65 64
Figure 1 In-gel comparison of concentrated Harvest material versus cell pellet material and mock harvest material.
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among three different production cell lines. Conse-
quently, the generated mock material was used for the
generation of the anti-HCP serum that will allow the
development of a UCB platform assay for determination
of HCP content. For each new biological produced with
UCB’s recombinant expression platform, the 80L mock
growth and HCP profiles will be compared with the 80L
production profile to ensure that the platform assay is
suitable for the new molecule.
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